Janssen returns obesity and diabetes treatment rights to Hanmi Pharmaceutical
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]
Hanmi Pharmaceutical announced on July 3 that its partner, Janssen, has returned the rights of obesity / diabetes treatment (HM12525A).
Hanmi Pharmaceutical does not return $ 105 million (about 123 billion won) of the down payment already received even if the drug is returned.
Hanmi Pharmaceutical said, "The recent two-phase clinical trials for Janssen's completed obesity patients showed that the target of weight loss, the primary end point, was reached, but the blood glucose control in obese patients with diabetes?
was below the internal standard. I have been informed, "he said.
Hanmi Pharmaceutical said, "Although Janssen has notified us of the right to return, the results of the Phase 2 clinical trials have proven that the effect as non-IF is sufficient," he said.
Press Release[/caption]
Hanmi Pharmaceutical announced on July 3 that its partner, Janssen, has returned the rights of obesity / diabetes treatment (HM12525A).
Hanmi Pharmaceutical does not return $ 105 million (about 123 billion won) of the down payment already received even if the drug is returned.
Hanmi Pharmaceutical said, "The recent two-phase clinical trials for Janssen's completed obesity patients showed that the target of weight loss, the primary end point, was reached, but the blood glucose control in obese patients with diabetes?
was below the internal standard. I have been informed, "he said.
Hanmi Pharmaceutical said, "Although Janssen has notified us of the right to return, the results of the Phase 2 clinical trials have proven that the effect as non-IF is sufficient," he said.
